ABSTRACT
Background: Coronavirus belongs to the phylum Incertaesedis, Nidovirales order, Or-thocononaviridae subfamily. and spring up from the family of viruses that can cause the common cold, fever, shortness of breath, aches, chills, loss of smell, etc. Objective(s): As we all know;coronavirus has affected the whole world, and many patients died due to it. As the prevalence of this disease has risen, many myths have also originated like the effect of temperature on the virus;is this virus surely killed by the effect of temperature? Is the effect of this virus is more on the old age patients? In the presented compilation, we have tried to expose the actual reality behind these myths and also tried to find the morphological alteration of coronavirus from the other viruses. Method(s): The recent updates on this virus have been obtained from search engines like Pub med and Google scholar, by using COVID-19, coronavirus, Pandemic corona keywords. Result(s): After a huge search on the temperature effect on this disease, it was evident that there is no effect of temperature on the coronavirus. Due to the immunity factor, it showed its worst effect on old age people in many countries. Conclusion(s): The structure, symptoms and incubation period of coronavirus have been described in this review article. We have summarized how the coronavirus is different from others, and the effects of temperature and old age have also been discussed.Copyright © 2021 Bentham Science Publishers.
ABSTRACT
In the present hour, the COVID-19 pandemic needs no introduction. There is continuous and keen research in progress in order to discover or develop a suitable therapeutic candidate/vaccine against the fatal, severe acute respiratory syndrome causing coronavirus (SARS-CoV-2). Drug repurposing is an approach of utilizing the therapeutic potentials of previously approved drugs against some new targets or pharmacological responses. In the presented work, we have evaluated the RNA dependent RNA polym-erase (RdRp) inhibitory potentials of FDA approved anti-viral drugs remdesivir, ribavirin, sofosbuvir and galidesivir through molecular docking. The studies were carried out using MOE 2019.0102 software against RdRp (PDB ID:7BTF, released on 8th April, 2020). All four drugs displayed good docking scores and significant binding interactions with the amino acids of the receptor. The docking protocol was validated by redocking of the ligands and the root mean square deviation (RMSD) value was found to be less than 2. The 2D and 3D binding patterns of the drugs were studied and evaluated with the help of poses. The drugs displayed excellent hydrogen bonding interactions within the cavity of the receptor and displayed comparable docking scores. These drugs may serve as new therapeutic candidates or leads against SARS-CoV-2.Copyright © 2020 Bentham Science Publishers.
ABSTRACT
Although there is continuous work in progress in some of the above mentioned approaches, but there is still no drug/vaccine available to treat COVID-19. Drug repurposing offers an economical and rapid strategy to discover a potential therapeutic agent in the current hectic situation. This compilation may be helpful to the researchers, drug developers and health agencies to look into the matter and work against the possible targets to develop a therapeutic candidate against COVID-19. The challenge associated with drug repurposing is the inadequate efficacy of single therapeutic candidate. Another complication associated with this approach is to search and analyze the huge amount of previously reported data to make efficient and effective use against a new indication. The complex/unclear events of the pathophysiology of SARS-CoV-2 also offer a great challenge to select a candidate for repurposing.